No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Renal impairment does not require a dose change for the granisetron patch. Limits and monitoring Use the transdermal application and timing instructions. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 4, posted Nov 05, 2024 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Start injectable hydromorphone at 25-50% of the usual initial dose, depending on renal impairment severity. Limits and monitoring Titrate cautiously and monitor sedation and respiratory status. This summary concerns the injection. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 6, posted Aug 31, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Measured creatinine clearance, mL/min Renal action or finding At measured CrCl below 60 mL/min or in ESRD, reduce the initial once-daily dose from 15 to 7.5 mg/kg. Give after hemodialysis on dialysis days. Limits and monitoring Monitor blood counts closely. Confirm Hydrea and its labeled indication before applying the regimen. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 21, posted Jan 28, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Measured creatinine clearance, mL/min Renal action or finding Halve the usual Siklos dose when CrCl is below 60 mL/min or ESRD is present. Give the dose after hemodialysis on treatment days. Limits and monitoring Verify the age-specific initial dose, tablet strength and hematologic monitoring. Review 2 product or source cautions
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 13, posted Jan 08, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Insufficient evidence
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Renal impairment has not been specifically studied for icosapent ethyl. Limits and monitoring The absence of renal studies provides no quantitative adjustment or dialysis schedule. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 7, posted Apr 09, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Cockcroft-Gault CrCl, mL/min Renal action or finding Adult CrCl below 90 mL/min requires a lower imipenem/cilastatin IV regimen. Use the label's renal table and the row for the intended regimen and organism susceptibility. Limits and monitoring Use stable serum creatinine. The label restricts use below CrCl 15 unless hemodialysis is instituted within 48 hours. Confirm seizure risk and HD timing. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 35, posted Oct 23, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Insufficient evidence
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding The safety and efficacy of inotuzumab ozogamicin in ESRD remain unknown, whether or not the patient receives hemodialysis. Limits and monitoring Verify the patient's modality and oncology regimen before applying any renal recommendation. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 8, posted Feb 09, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Reduced kidney function can change insulin requirements. Monitor glucose more often and titrate to the measured response. Limits and monitoring Confirm insulin identity, concentration and delivery device. The cited renal guidance gives no fixed percentage reduction. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 18, posted Jul 25, 2023 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Reduced kidney function can change insulin requirements. Monitor glucose more often and titrate to the measured response. Limits and monitoring Confirm insulin identity, concentration and delivery device. The cited renal guidance gives no fixed percentage reduction. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 34, posted Jan 22, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Reduced kidney function can change insulin requirements. Monitor glucose more often and titrate to the measured response. Limits and monitoring Confirm insulin identity, concentration and delivery device. The cited renal guidance gives no fixed percentage reduction. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 24, posted Oct 10, 2024 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Reduced kidney function can change insulin requirements. Monitor glucose more often and titrate to the measured response. Limits and monitoring Confirm insulin identity, concentration and delivery device. The cited renal guidance gives no fixed percentage reduction. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 35, posted Jul 02, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Reduced kidney function can change insulin requirements. Monitor glucose more often and titrate to the measured response. Limits and monitoring Confirm insulin identity, concentration and delivery device. The cited renal guidance gives no fixed percentage reduction. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 25, posted Jun 12, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Return to top Find another drug
